Table 5 Patient characteristics of cases and matched controls
Cases (with incident malignancy) | Matched controls | P | |
|---|---|---|---|
N | 74 | 74 | |
Characteristics at study entry | |||
Females# n (%) | 52 (70.3) | 52 (70.3) | n.a. |
Age# (mean, SD) | 61.3 (8.9) | 61.4 (8.5) | 0.97 |
Observation time# (years) (median, IQR) | 2.9 (1.8, 4.0) | 2.9 (1.6, 3.9) | 0.25 |
DAS28# (mean, SD) | 5.6 (1.0) | 5.7 (1.0) | 0.31 |
Smoking status# | |||
Nonsmoker | 16 (21.6) | 16 (21.6) | n.a. |
Smoker n (%) | 19 (25.7) | 19 (25.7) | |
Unknown status n (%) | 39 (52.7) | 39 (52.7) | |
Disease duration (years) (median, IQR) | 7 (3,14) | 9 (5,16) | 0.22 |
Functional status, FFbH (mean, SD) | 57.1 (22.3) | 63.2 (22.6) | 0.058 |
Characteristics at follow-up | |||
DAS28 (mean, SD)$ | 5.0 (1.2) | 4.9 (1.2) | 0.41 |
Ever exposed to biologics n (%) | 44 (59.5) | 45 (60.8) | 1.0 |
Ever exposed to anti-TNFα agents & | 44 (59.5) | 44 (59.5) | 1.0 |
Ever exposed to anakinra& | 5 (6.8) | 5 (6.8) | 1.0 |
Among them | |||
Cases with solid tumors (n = 68) | |||
Ever exposed to biologics | 39 (57.4) | 43 (63.2) | 0.56 |
Ever exposed to anti-TNFα agents | 39 (57.4) | 42 (61.8) | 0.70 |
Ever exposed to anakinra | 5 (7.4) | 5 (7.4) | 1.0 |
Cases with non-Hodgkin's Lymphoma (n = 6) | |||
Characteristics at study entry | |||
Females # n(%) | 5 (83.3) | 5 (83.3) | n.a. |
Age # (mean, SD) | 65.2 (6.5) | 66.8 (8.0) | 0.13 |
Disease duration | 5.5 (4,13) | 7 (5,11) | 0.53 |
Functional status, FFbH (mean, SD) | 52.8 (31.4) | 54.2 (27.5) | 0.90 |
DAS28 # (mean, SD) | 5.9 (0.6) | 6.2 (0.5) | 0.29 |
Characteristics at follow-up | |||
DAS28 (mean, SD) $ | 5.2 (0.7) | 5.5 (0.7) | 0.14 |
Ever exposed to anti-TNFα agents | 5 (83.3) | 2 (33.3) | 0.38 |